{"entity":{"type":"insider","cik":"0001661254","url":"/insider/0001661254","json_url":"/insider/0001661254.json","name":"Van Naarden Jacob","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":139,"n_filings":18,"first":"2017-08-16","last":"2025-08-13","span_basis":"filed_date"},"name_variants":[{"name":"Van Naarden Jacob","source":"filing","n_filings":18,"first_seen":"2017-08-16","last_seen":"2025-08-13"}],"transactions":[{"id":4057211,"accession":"0000059478-25-000218","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000059478-25-000218","line_url":"/filing/0000059478-25-000218#line-1","is_derivative":false,"issuer_cik":"0000059478","issuer_name":"ELI LILLY & Co","issuer_ticker":"LLY","issuer_name_source":null,"issuer_url":"/issuer/0000059478","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (EVP & Pres., Lilly Oncology)","role_mark":"O","role_mark_label":"Officer (EVP & Pres., Lilly Oncology)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Pres., Lilly Oncology","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":647.36,"price_display":"647.36","price_state":"stated","total_value":647360.0,"total_display":"647,360.00","total_whole":"647,360","shares_owned_after":20561.985,"shares_owned_after_display":"20,561.98","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-13","filed_date":"2025-08-13","scope":"insider"},{"id":6057531,"accession":"0001567619-18-007788","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001567619-18-007788","line_url":"/filing/0001567619-18-007788","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4500.0,"shares_display":"4,500","price_per_share":137.35108222222223,"price_display":"137.35","price_state":"stated","total_value":618079.87,"total_display":"618,079.87","total_whole":"618,080","shares_owned_after":15241.0,"shares_owned_after_display":"15,241","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-11","filed_date":"2018-12-12","scope":"insider","n_lines":6},{"id":6057512,"accession":"0001567619-18-007788","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001567619-18-007788","line_url":"/filing/0001567619-18-007788","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4500.0,"shares_display":"4,500","price_per_share":133.652,"price_display":"133.65","price_state":"stated","total_value":601434.0,"total_display":"601,434.00","total_whole":"601,434","shares_owned_after":14500.0,"shares_owned_after_display":"14,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-10","filed_date":"2018-12-12","scope":"insider","n_lines":7},{"id":6842960,"accession":"0001567619-18-007050","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0001567619-18-007050","line_url":"/filing/0001567619-18-007050","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4500.0,"shares_display":"4,500","price_per_share":141.6624911111111,"price_display":"141.66","price_state":"stated","total_value":637481.21,"total_display":"637,481.21","total_whole":"637,481","shares_owned_after":16081.0,"shares_owned_after_display":"16,081","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-27","filed_date":"2018-11-28","scope":"insider","n_lines":11},{"id":6842909,"accession":"0001567619-18-007050","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001567619-18-007050","line_url":"/filing/0001567619-18-007050","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5500.0,"shares_display":"5,500","price_per_share":153.13169454545454,"price_display":"153.13","price_state":"stated","total_value":842224.32,"total_display":"842,224.32","total_whole":"842,224","shares_owned_after":16000.0,"shares_owned_after_display":"16,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-26","filed_date":"2018-11-28","scope":"insider","n_lines":5},{"id":6427966,"accession":"0001567619-18-003762","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001567619-18-003762","line_url":"/filing/0001567619-18-003762","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4500.0,"shares_display":"4,500","price_per_share":162.64084244444444,"price_display":"162.64","price_state":"stated","total_value":731883.791,"total_display":"731,883.79","total_whole":"731,884","shares_owned_after":15306.0,"shares_owned_after_display":"15,306","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-04","filed_date":"2018-10-05","scope":"insider","n_lines":5},{"id":6427950,"accession":"0001567619-18-003762","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001567619-18-003762","line_url":"/filing/0001567619-18-003762","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5500.0,"shares_display":"5,500","price_per_share":167.15955454545454,"price_display":"167.16","price_state":"stated","total_value":919377.55,"total_display":"919,377.55","total_whole":"919,378","shares_owned_after":14000.0,"shares_owned_after_display":"14,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-03","filed_date":"2018-10-05","scope":"insider","n_lines":5},{"id":6842641,"accession":"0001567619-18-002676","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001567619-18-002676","line_url":"/filing/0001567619-18-002676","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4500.0,"shares_display":"4,500","price_per_share":165.97846,"price_display":"165.98","price_state":"stated","total_value":746903.07,"total_display":"746,903.07","total_whole":"746,903","shares_owned_after":15500.0,"shares_owned_after_display":"15,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-13","filed_date":"2018-09-14","scope":"insider","n_lines":3},{"id":6842627,"accession":"0001567619-18-002676","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001567619-18-002676","line_url":"/filing/0001567619-18-002676","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5500.0,"shares_display":"5,500","price_per_share":166.59560414545456,"price_display":"166.60","price_state":"stated","total_value":916275.8228,"total_display":"916,275.82","total_whole":"916,276","shares_owned_after":16559.0,"shares_owned_after_display":"16,559","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-12","filed_date":"2018-09-14","scope":"insider","n_lines":6},{"id":6449227,"accession":"0001567619-18-001208","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001567619-18-001208","line_url":"/filing/0001567619-18-001208#line-9","is_derivative":false,"issuer_cik":"0001581720","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001581720","owner_cik":"0001661254","owner_name":"Van Naarden Jacob","owner_display_name":"Van Naarden Jacob","owner_url":"/insider/0001661254","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3199.0,"shares_display":"3,199","price_per_share":159.907,"price_display":"159.91","price_state":"stated","total_value":511542.493,"total_display":"511,542.49","total_whole":"511,542","shares_owned_after":14401.0,"shares_owned_after_display":"14,401","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-14","filed_date":"2018-08-15","scope":"insider"}],"collapsed":true,"next_cursor":"2018-08-14|6449227","ledger_fault":false,"count":{"value":139,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":138,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":139},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000059478","name":"ELI LILLY & Co","url":"/issuer/0000059478","role":"Officer (EVP & Pres., Lilly Oncology)","n_filings":1,"first_seen":"2025-08-13","last_seen":"2025-08-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001581720","name":"Loxo Oncology, Inc.","url":"/issuer/0001581720","role":"Officer (Chief Business Officer)","n_filings":17,"first_seen":"2017-08-16","last_seen":"2018-12-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001661254","retrieved_at":"2026-08-27T00:49:40+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}